EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Migraine across the menopausal transition and beyond: A narrative review

Tal Friedman Korn iD, Carolyn Bernstein iD

Headache: The Journal of Head and Face Pain · 2026-06 · 66 (6) · 1390-1404

DOI: 10.1111/head.70071 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 03.04.2026. Verfasst von Tal Friedman Korn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Menopause. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 220 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Migraine is a neurologic disorder that disproportionately affects women and undergoes important changes across the menopausal transition. Estrogen fluctuations contribute to migraine expression and underlie the 3:1 female‐to‐male prevalence. Perimenopause, marked by hormonal variability and rising cardiometabolic risk, presents unique diagnostic and therapeutic challenges. Despite its high prevalence, evidence specific to perimenopausal and postmenopausal women remains limited.

Objective

This review synthesizes current evidence on the epidemiology, pathophysiology, and management of migraine across the menopausal transition, with attention to hormone therapy, comorbidities, and emerging treatments.

Methods

We conducted a narrative review of clinical and translational studies published within the past 5 years, supplemented by seminal mechanistic, epidemiologic, and guideline‐defining studies published earlier. Relevant guideline statements from neurology, gynecology, and cardiovascular societies were also incorporated.

Results

Unstable estradiol and progesterone levels during perimenopause can worsen migraine frequency and predictability. Migraine without aura often improves after menopause, whereas migraine with aura tends to persist and independently increases the risk of ischemic stroke and other vascular events. Midlife comorbidities—including vasomotor symptoms, sleep disturbance, mood disorders, and metabolic disease—further complicate management. Menopausal hormone therapy has variable effects. Oral estrogen, particularly at higher doses, may worsen migraine and elevate vascular risk, especially in women with aura. In contrast, low‐dose transdermal estrogen—recommended by the North American Menopause Society—appears safer and better tolerated. Continuous progestogen regimens may reduce withdrawal‐related attacks compared with cyclic regimens. Nonhormonal options, particularly selective norepinephrine reuptake inhibitors, may be considered when vasomotor symptoms coexist, whereas migraine‐specific prevention should follow established evidence‐based therapies. Traditional migraine therapies (triptans, NSAIDs, beta‐blockers, topiramate, antidepressants) remain central but require tailoring to vascular, bone, and metabolic health. Newer agents—including calcitonin gene‐related peptide monoclonal antibodies, gepants, and ditans—offer effective, non‐vasoconstrictive alternatives, especially for women with cardiovascular contraindications.

Conclusions

Migraine during the menopausal transition reflects the interplay between hormonal dynamics and systemic health. Management requires balancing efficacy with vascular and metabolic safety while incorporating patient preferences. Evidence gaps include the lack of trials stratified by menopausal stage or migraine subtype. Multidisciplinary, menopause‐informed care and prospective studies are needed to optimize outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersMenopauseHumansFemaleEstrogen Replacement TherapyPerimenopauseEstrogens

Stichwörter der Autor:innen

hormone therapymenopausal transitionmigraine

Substanzen

Estrogens

Autor:innen und Institutionen

  • Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Tal Friedman Korn, Carolyn Bernstein

Zitieren

APA

Korn, T. F., & Bernstein, C. (2026). Migraine across the menopausal transition and beyond: A narrative review. Headache: The Journal of Head and Face Pain, 66(6), 1390-1404. https://doi.org/10.1111/head.70071

Vancouver

Korn TF, Bernstein C. Migraine across the menopausal transition and beyond: A narrative review. Headache: The Journal of Head and Face Pain. 2026;66(6):1390-1404. doi:10.1111/head.70071

BibTeX
@article{Korn2026,
  author = {Korn, Tal Friedman and Bernstein, Carolyn},
  title = {Migraine across the menopausal transition and beyond: A narrative review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1390--1404},
  doi = {10.1111/head.70071}
}
Kostenlos starten →